{"product_id":"89bio-bcg-matrix","title":"89bio Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where 89bio’s products land—Stars, Cash Cows, Dogs, or Question Marks? This preview teases the shifts and signals, but the full BCG Matrix gives quadrant-by-quadrant placement, data-backed recommendations, and a strategic roadmap you can act on. Purchase the complete report for a ready-to-use Word analysis plus an Excel summary—clear insights to guide investment, product focus, and competitive moves without another minute of guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin in NASH\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePegozafermin, an FGF21 analog and 89bio's lead asset in NASH, shows strong clinical signals and sits in a NASH market projected to reach roughly $24B by 2030 with ~20% CAGR (2024 estimates). If momentum holds it behaves like a Star: high growth, leadership potential, and heavy R\u0026amp;D spend; maintaining funding for pivotal trials, payer groundwork, and KOL advocacy is pivotal. Protect the lead via smart trial design and a crisp safety narrative.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin in SHTG\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSHTG is urgent and visible as cardiometabolic risk climbs: NHANES estimates ~1.7% of US adults have triglycerides ≥500 mg\/dL (~4.4M people) and global diabetes prevalence exceeds 10%, amplifying demand for SHTG therapies. Early pegozafermin data show promising TG-lowering signals and unmet need places the program in the Star lane if execution remains tight. Double down on regulatory pathing and real-world evidence prep now. Build specialist awareness to lock in share later.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFGF21 platform credibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngineered FGF21 analog know‑how is scarce—fewer than 20 clinical‑stage FGF21 programs existed globally in 2024, making platform expertise highly valuable. Deep FGF21 platform capability can create a leadership halo across liver and metabolic care, a market projected above $30 billion by 2030 (2024 consensus). Continued publishing and presenting keeps 89bio owning the scientific conversation, attracting partners, talent, and capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory momentum: securing designations, clean FDA dialogues, and agreed clear endpoints accelerates 89bio’s competitive positioning in a fast-growing NASH\/rare liver space; smoother paths typically lead to share appreciation.\u003c\/p\u003e\n\u003cp\u003eMaintain proactive engagement and submission readiness to convert regulatory clarity into value; this strategy burns cash but materially thickens the regulatory moat.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003edesignations: priority review \/ breakthrough engagement\u003c\/li\u003e\n\u003cli\u003eclean dialogues: reduces endpoint risk\u003c\/li\u003e\n\u003cli\u003esubmission readiness: readiness drives timing\u003c\/li\u003e\n\u003cli\u003etrade-off: higher burn today, stronger moat tomorrow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOL and trial network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003eKOL and trial network\u003c\/h3\u003eHigh-performing sites and advocates are hard to replicate; in a hot NASH\/steatohepatitis market the KOL+site network functions as a Star asset, driving faster enrollment, higher retention and payer visibility. Nurture consistency, speed and patient access and scale footprint before competitors crowd the field.\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNetwork scarcity\u003c\/li\u003e\n\u003cli\u003eEnrollment velocity\u003c\/li\u003e\n\u003cli\u003eRetention advantage\u003c\/li\u003e\n\u003cli\u003eFirst-mover scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase 2 FGF21 shows strong NASH\/SHTG signals; markets: \u003cstrong\u003e$24B\u003c\/strong\u003e NASH, \u003cstrong\u003e$30B+\u003c\/strong\u003e metabolic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin is a Star: strong Phase 2 signals in NASH\/SHTG, target markets ~$24B (NASH) and \u0026gt;$30B (metabolic) by 2030 (2024 estimates), ~20% CAGR, and SHTG prevalence ~1.7% US adults (~4.4M). Platform scarcity (\u0026lt;20 FGF21 programs in 2024) plus regulatory\/KOL momentum support leadership if execution and funding persist.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNASH market\u003c\/td\u003e\n\u003ctd\u003e$24B by 2030 (2024 est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFGF21 programs (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSHTG US\u003c\/td\u003e\n\u003ctd\u003e1.7% (~4.4M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG analysis of 89bio's products, identifying Stars, Cash Cows, Question Marks and Dogs with clear investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix that maps 89bio units into clear quadrants, cutting analysis time and easing exec decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo marketed therapies yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNo true Cash Cow—clinical-stage 89bio (ETNB) has no marketed therapies or steady low‑growth revenue as of 2024. Name this explicitly to avoid strategy drift. Map how pegozafermin can mature into a Cash Cow post‑launch (pricing, market access, uptake timelines) and set cost discipline now so target margins materialize on schedule.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture NASH label durability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf approved and the market matures, sustained share turns into cash generation; that's the classic Cow: leader, low incremental promo and reliable cash flow. As of 2024 there are no FDA‑approved pharmacologic therapies for NASH and NAFLD affects about 25% of adults globally, supporting a large addressable market. Prepare lifecycle management, real‑world outcomes and coverage renewals and lock in guideline inclusion to cement positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture SHTG chronic scripts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFuture SHTG chronic scripts could produce stable repeat prescriptions with modest growth once established; chronic diseases drive 90% of US healthcare costs (CDC, 2024) supporting predictable demand. Efficiency and adherence programs — medication adherence averages ~50% in developed countries (WHO) — can materially boost margin. Early investment in patient support and streamlined distribution reduces churn and targets steady net revenue with minimal surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlatform royalties (post-partner)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSelect partnered deals can yield low‑growth, high‑margin royalty streams consistent with Cash Cow dynamics; typical pharma royalty rates range around 10–20% and require minimal promotion spend, supporting \u0026gt;60–70% contribution margins on royalty income. Structure upfront milestones and durable royalty tiers now to secure downstream stability and retain rights where economics are strongest.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eroyalty rate: 10–20%\u003c\/li\u003e\n\u003cli\u003emargin profile: \u0026gt;60% contributn\u003c\/li\u003e\n\u003cli\u003emilestones: align for long‑term streams\u003c\/li\u003e\n\u003cli\u003erights: prioritize high‑economics territories\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing efficiency at scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManufacturing efficiency at scale: as biologics scale, COGS can decline roughly 20–30% and batch yields improve, swelling operating cash flow—critical for 89bio as it transitions assets toward commercial maturity; treat ops excellence as a future Cash Cow and prioritize supplier lock-ins, validated second sources, and automated QA to protect margin.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLock reliable suppliers\u003c\/li\u003e\n\u003cli\u003eValidate second sources\u003c\/li\u003e\n\u003cli\u003eAutomate QA\u003c\/li\u003e\n\u003cli\u003eSmall opex tweaks can swing cashflow materially\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo marketed product in 2024 - NASH therapy must nail price, access to hit \u0026gt;60% margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNo Cash Cow in 2024—89bio has no marketed products; pegozafermin must hit pricing, access and margin targets to become one.\u003c\/p\u003e\n\u003cp\u003eNASH\/NAFLD ~25% adult prevalence globally (2024); guideline inclusion and payer coverage drive steady uptake.\u003c\/p\u003e\n\u003cp\u003ePartner royalties 10–20%, scaled COGS −20–30% → potential \u0026gt;60% contribution margins; secure suppliers, automate QA, patient support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNAFLD prevalence\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty range\u003c\/td\u003e\n\u003ctd\u003e10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS decline est.\u003c\/td\u003e\n\u003ctd\u003e20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003e89bio BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact BCG Matrix report you'll receive after purchase. No watermarks or demo content—just a fully formatted, editable document built for strategic clarity. Crafted by strategy pros with market-backed analysis, it's ready to print, present, or plug into your planning. Once bought, the same file is yours to download and use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScattered non-core discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScattered non-core discovery projects are nice-to-have side work that dilute focus and rarely pay back; per the BCG framework Dogs sit in low-growth, low-share quadrants and should be cut or paused ruthlessly to free budget for core assets that move the needle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUndifferentiated biomarker hunts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUndifferentiated biomarker hunts at 89bio often stall without a clear path to label impact, consuming cash and management bandwidth while markets move on. Set sharp go\/no-go gates—require biomarker utility evidence within 12 months or after the first pivotal cohort readout. If predefined utility metrics aren’t met, stop spend and reallocate capital to higher-conviction programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremature geographies expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEntering tiny markets early drains capital and attention; clinical-stage biotechs in 2024 faced median cash runways near 18 months, making low-return market bets costly. Low share, low growth, minimal learning place such programs squarely in Dog territory. Sequence markets by access and size—prioritize indications where 2024 prevalence and commercial potential justify development spend. Focus where uptake can be meaningful and scalable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy vendor contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003eLegacy vendor contracts\u003c\/h3\u003e Overpriced, underperforming vendors trap cash without adding speed or quality, a clear Dog in the P\u0026amp;L for 89bio; biotech outsourcing accounts for roughly 40–60% of R\u0026amp;D spend (2024 industry range), so vendor inefficiency materially depresses runway. Rebid, renegotiate, or exit underperformers — rebidding can yield 10–25% savings in vendor fees based on 2024 CRO benchmarking studies — and redirect savings to pivotal clinical milestones.\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: cash-drain\u003c\/li\u003e\n\u003cli\u003eTag: 40–60% R\u0026amp;D outsourced (2024)\u003c\/li\u003e\n\u003cli\u003eTag: potential 10–25% savings on rebid (2024 benchmarks)\u003c\/li\u003e\n\u003cli\u003eTag: redirect to pivotal trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad MOA distractions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChasing multiple mechanisms beyond FGF21 dilutes 89bios core value proposition, creating slow growth, low differentiation and a thin competitive share in crowded metabolic\/NASH markets.\u003c\/p\u003e\n\u003cp\u003eSunset programs that do not reinforce the FGF21 platform, concentrate proof-of-concept efforts and redeploy capital toward lead assets to maximize probability of pivotal success.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: reinforce FGF21 platform\u003c\/li\u003e\n\u003cli\u003eAction: sunset non-core MOAs\u003c\/li\u003e\n\u003cli\u003eOutcome: concentrate proof and capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCut non-core dogs; set \u003cstrong\u003e12\u003c\/strong\u003e-mo biomarker gate; rebid vendors to free \u003cstrong\u003e10–25%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: non-core discovery and small-market programs dilute focus, consume cash and management time and show low growth\/low share metrics at 89bio.\u003c\/p\u003e\n\u003cp\u003eSet 12-month biomarker utility gates; stop if no clear label path after first pivotal cohort readout to preserve runway (2024 median cash runway ~18 months).\u003c\/p\u003e\n\u003cp\u003eRebid legacy vendors (industry 2024 outsourcing 40–60%) to save 10–25% and reallocate to FGF21 pivotal assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash runway (median)\u003c\/td\u003e\n\u003ctd\u003e~18 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D outsourced\u003c\/td\u003e\n\u003ctd\u003e40–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebid savings\u003c\/td\u003e\n\u003ctd\u003e10–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNASH combo strategies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCombining pegozafermin with complementary MOAs could unlock outsized efficacy; the NASH therapeutics market is a high-growth opportunity projected at about 16.7 billion USD by 2030 with ~11% CAGR (2024 estimates), but 89bio share is unknown—classic Question Mark. Invest in smart, small phase 2 combo trials to de-risk and prioritize scaling only where synergy yields meaningful signals (eg, ≥30% relative liver fat reduction or fibrosis stage improvement).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarlier-stage cardiometabolic uses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEarlier-stage cardiometabolic uses target huge unmet need—CDC estimates 96 million US adults have prediabetes and WHO reported ~650 million adults with obesity (2016), yet 89bio’s current share is minimal. Potential upside is large but clinical proof is pending, so prioritize small, targeted PoCs with tight metabolic and glycemic endpoints. Use rapid go\/no-go criteria and pre-specified futility thresholds to kill programs quickly if signals aren’t compelling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin real-world evidence engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin’s real-world evidence engine can drive payer confidence and physician comfort for 89bio (ETNB) by turning early clinical signals into coverage narratives, though building RWE is costly and early-stage in 2024. Returns start small and compound as longitudinal registry and claims signals accumulate; stand up a pragmatic registry plus claims analytics to capture treatment patterns and outcomes. Iterate quickly to surface value stories for payers and clinicians.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAPAC (UN 2024 est. 4.7B), LATAM (660M) and MENA (500M) offer high growth markets for 89bio but current commercial share is low; execution risk remains material given regulatory, reimbursement and distribution complexity. Target partners with operational scale and pricing alignment, structuring stage-gate deals tied to adoption and reimbursement milestones to limit downside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCourt partners with operational muscle and aligned pricing\u003c\/li\u003e\n\u003cli\u003eStage-gate deals against adoption and reimbursement milestones\u003c\/li\u003e\n\u003cli\u003eAPAC 4.7B, LATAM 660M, MENA 500M (UN 2024 est.)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-acting or depot formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLong-acting\/depot formulations could shift adherence and market share by improving dosing convenience; in 2024 long-acting injectables reported adherence uplifts up to 30% in select indications. R\u0026amp;D is heavy with high uncertainty—industry Phase I-to-approval success ~10% and development costs commonly \u0026gt;$1B. Prototype, test patient preference, and model cost-to-benefit early; advance only if it sharpens differentiation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTag: adherence +20–30%\u003c\/li\u003e\n\u003cli\u003eTag: success rate ~10%\u003c\/li\u003e\n\u003cli\u003eTag: development cost \u0026gt;$1B\u003c\/li\u003e\n\u003cli\u003eTag: advance only if differentiates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCombos for cardiometabolic disease: prioritize small phase‑2 PoCs and payer‑focused RWE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin combos and cardiometabolic expansions are high-upside Question Marks: NASH market ~16.7B by 2030 (~11% CAGR, 2024 est.), prediabetes 96M US adults, obesity ~650M (WHO 2016), but 89bio share minimal. Prioritize small phase‑2 PoCs with ≥30% liver fat or fibrosis signals, strict futility gates, and pragmatic RWE to build payer value. Target APAC\/LATAM\/MENA via stage‑gate partnerships; long‑acting formulations only if net benefit justifies ~\u0026gt; $1B dev cost and ~10% approval odds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNASH TAM (2030)\u003c\/td\u003e\n\u003ctd\u003e16.7B (11% CAGR, 2024 est.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Prediabetes\u003c\/td\u003e\n\u003ctd\u003e96M (CDC)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Obesity\u003c\/td\u003e\n\u003ctd\u003e650M (WHO 2016)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC \/ LATAM \/ MENA\u003c\/td\u003e\n\u003ctd\u003e4.7B \/ 660M \/ 500M (UN 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLAI adherence uplift\u003c\/td\u003e\n\u003ctd\u003eup to 30% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDev cost \/ success\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B \/ ~10% success\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097833312604,"sku":"89bio-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/89bio-bcg-matrix.png?v=1781787167","url":"https:\/\/pestel-analysis.com\/products\/89bio-bcg-matrix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}